Home

In December 2025, the Centers for Medicare & Medicaid Services (CMS) announced two major initiatives to expand access to obesity management medications for Medicare and Medicaid beneficiaries: the Medicare GLP-1 Bridge program and the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model. CMS has announced an indefinite delay of the BALANCE Model’s Medicare Part D component due... Read more

Enacted in 2022, the Inflation Reduction Act (IRA) introduced significant reforms aimed at reducing the financial burden of prescription drug costs for Medicare Part D beneficiaries.

A new report from MAPRx, however, shows that as a larger share of liability has shifted from the federal government to plans and pharmaceutical manufacturers, plan behavior is seen changing... Read more

The MAPRx coalition has championed policies in Part D that improve the affordability of medications and beneficiary access to those medications, including provisions of the Inflation Reduction Act (IRA) that establish an out-of-pocket cap in Part D and the Medicare Prescription Payment Plan. MAPRx strongly opposes the GUARD Model and urges CMS to abandon this proposal and withdraw the model.... Read more

The Medicare prescription drug benefit (Medicare Part D) has been an enormous help to beneficiaries and a policy success story by providing coverage for prescription drugs. The program filled a major gap in Medicare’s benefits and has done so with consistently high satisfaction among beneficiaries. However, for the MPPP to have a greater impact and operate as intended by Congress... Read more

Medicare Part D prescription drug plans will have an out-of-pocket maximum of $2,100 for 2026 and beneficiaries can also opt in to the Medicare Prescription Payment Plan (MPPP)—a new program that lets you pay for prescriptions in monthly installments. The MAPRx Coalition has created this patient guide with more information.